ZA9610060B - Thyroxine/cyclodextrin complexes and pharmaceutical compositions containing the same. - Google Patents

Thyroxine/cyclodextrin complexes and pharmaceutical compositions containing the same.

Info

Publication number
ZA9610060B
ZA9610060B ZA9610060A ZA9610060A ZA9610060B ZA 9610060 B ZA9610060 B ZA 9610060B ZA 9610060 A ZA9610060 A ZA 9610060A ZA 9610060 A ZA9610060 A ZA 9610060A ZA 9610060 B ZA9610060 B ZA 9610060B
Authority
ZA
South Africa
Prior art keywords
thyroxine
pct
pharmaceutical compositions
cyclodextrin complexes
same
Prior art date
Application number
ZA9610060A
Other languages
English (en)
Inventor
Wilfried Fischer
Daniel Bracher
Original Assignee
Hexal Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hexal Ag filed Critical Hexal Ag
Publication of ZA9610060B publication Critical patent/ZA9610060B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nanotechnology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ZA9610060A 1995-11-29 1996-11-29 Thyroxine/cyclodextrin complexes and pharmaceutical compositions containing the same. ZA9610060B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
HU9503407A HUT75956A (en) 1995-11-29 1995-11-29 Pharmaceutical composition containing thyroxine

Publications (1)

Publication Number Publication Date
ZA9610060B true ZA9610060B (en) 1997-09-09

Family

ID=10987407

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9610060A ZA9610060B (en) 1995-11-29 1996-11-29 Thyroxine/cyclodextrin complexes and pharmaceutical compositions containing the same.

Country Status (7)

Country Link
US (1) US5856359A (de)
EP (1) EP0814844B1 (de)
AT (1) ATE223236T1 (de)
DE (1) DE69623449D1 (de)
HU (1) HUT75956A (de)
WO (1) WO1997019703A2 (de)
ZA (1) ZA9610060B (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA98003802A (es) * 1995-11-14 2005-04-29 Abbott Gmbh & Co Kg Preparaciones de hormona tiroidea estabilizadas ymetodos para fabricar las mismas.
DE19821625C1 (de) * 1998-05-15 2000-01-05 Merck Patent Gmbh Pharmazeutische Zubereitung
DE19830246A1 (de) * 1998-07-07 2000-01-13 Merck Patent Gmbh Pharmazeutische Zubereitung
FI107018B (fi) * 2000-04-06 2001-05-31 Ipsat Therapies Oy Dermatologinen käyttö ja valmiste
FR2808195B1 (fr) * 2000-04-28 2006-12-08 Lyophilisation Alimentaire Patch cosmetique ou dermatologique lyophilise
US7163918B2 (en) * 2000-08-22 2007-01-16 New River Pharmaceuticals Inc. Iodothyronine compositions
US20030032675A1 (en) * 2001-02-15 2003-02-13 Franz G. Andrew Manufacture of thyroid hormone tablets having consistent active moiety amounts
US20030224047A1 (en) * 2001-02-15 2003-12-04 Franz G. Andrew Levothyroxine compositions and methods
US6555581B1 (en) 2001-02-15 2003-04-29 Jones Pharma, Inc. Levothyroxine compositions and methods
CA2440190A1 (en) * 2001-02-15 2003-08-28 King Pharmaceuticals, Inc. Levothyroxine compositions and methods
BR0207297A (pt) * 2001-02-15 2005-04-19 King Pharmaceuticals Inc Composição farmacêutica em forma sólida e método de preparar uma forma de dosagem sólida de um ingrediente farmaceuticamente ativo
US20030190349A1 (en) * 2001-08-10 2003-10-09 Franz G. Andrew Methods of stabilizing pharmaceutical compositions
US20030198671A1 (en) * 2001-08-10 2003-10-23 Franz G. Andrew Levothyroxine compositions having unique plasma AUC properties
US20030180353A1 (en) * 2001-08-10 2003-09-25 Franz G. Andrew Stabilized pharmaceutical compositions
US20030198667A1 (en) * 2001-08-10 2003-10-23 Franz Andrew G. Methods of producing dispersible pharmaceutical compositions
US20030203967A1 (en) * 2001-08-14 2003-10-30 Franz G. Andrew Levothyroxine compositions having unique Tmax properties
US20030195253A1 (en) * 2001-08-14 2003-10-16 Franz G. Andrew Unadsorbed levothyroxine pharmaceutical compositions, methods of making and methods of administration
US20030198672A1 (en) * 2001-08-14 2003-10-23 Franz G. Andrew Levothyroxine compositions having unique triidothyronine plasma AUC properties
US20030199587A1 (en) * 2001-08-14 2003-10-23 Franz G. Andrew Levothyroxine compositions having unique Cmax properties
US7101569B2 (en) 2001-08-14 2006-09-05 Franz G Andrew Methods of administering levothyroxine pharmaceutical compositions
US20030199586A1 (en) * 2001-08-14 2003-10-23 Franz G. Andrew Unique levothyroxine aqueous materials
US20030180356A1 (en) * 2001-10-29 2003-09-25 Franz G. Andrew Levothyroxine compositions having unique triiodothyronine Tmax properties
US6645526B2 (en) * 2001-11-13 2003-11-11 Mylan Pharmaceuticals, Inc. Storage stable thyroxine active drug formulations and methods for their production
US20030099699A1 (en) * 2001-11-13 2003-05-29 Hanshew Dwight D. Storage stable thyroxine active drug formulations and methods for their production
MXPA04007169A (es) * 2002-01-25 2004-10-29 Santarus Inc Suministro transmucosal de inhibidores de bomba de protones.
WO2003072047A2 (en) * 2002-02-22 2003-09-04 New River Pharmaceuticals Inc. Idothyronine compositions
US20040152783A1 (en) * 2002-11-05 2004-08-05 Olon Lawrence Peter Controlled absorption of admixed thyroid hormone formulations
GB0424526D0 (en) * 2004-11-05 2004-12-08 Controlled Therapeutics Sct Hydrogel delivery vehicle
EP1973524B1 (de) * 2006-01-06 2011-08-10 Intervet International BV Konzentrierte flüssige schilddrüsenhormonzusammensetzung
US20080160070A1 (en) * 2006-12-27 2008-07-03 Nexagen Usa Llc Transdermal vitamin b12 delivery patch
FR2912061A1 (fr) * 2007-02-01 2008-08-08 Aliscience Soc Par Actions Sim Complexes d'inclusion de cysteine, leur presparation et les compositions les contenant
US20090131380A1 (en) * 2007-11-16 2009-05-21 Pekka Heino Novel pharmaceutical composition for topical treatment of skin psoriasis and the treatment method thereof
US10328152B2 (en) 2011-06-16 2019-06-25 Nayan Patel Method for stabilization and delivery of therapeutic molecules
WO2017013591A1 (en) * 2015-07-22 2017-01-26 Leiutis Pharmaceuticals Pvt Ltd Stabilized liquid formulation of levothyroxine

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2827452A (en) * 1955-05-31 1958-03-18 Univ Minnesota Stabilization of materials
US4121975A (en) * 1976-08-20 1978-10-24 Syva Company Pretreatment of samples for polyiodothyronine assays
JPS62281855A (ja) * 1986-05-29 1987-12-07 Daikin Ind Ltd ビタミン，ビタミン誘導体，またはホルモンを含有する包接化合物
GB8613688D0 (en) * 1986-06-05 1986-07-09 Euro Celtique Sa Pharmaceutical composition
US5206025A (en) * 1989-05-24 1993-04-27 Rhone-Poulenc Sante Porous pharmaceutical form and its preparation
GB8920135D0 (en) * 1989-09-06 1989-10-18 Erba Carlo Spa Use of dehydrated cyclodextrins for improving drug dissolution
KR0166088B1 (ko) * 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도

Also Published As

Publication number Publication date
US5856359A (en) 1999-01-05
WO1997019703A3 (en) 1997-06-26
EP0814844A2 (de) 1998-01-07
WO1997019703A2 (en) 1997-06-05
EP0814844B1 (de) 2002-09-04
HUT75956A (en) 1997-05-28
DE69623449D1 (de) 2002-10-10
ATE223236T1 (de) 2002-09-15
HU9503407D0 (en) 1996-01-29

Similar Documents

Publication Publication Date Title
ZA9610060B (en) Thyroxine/cyclodextrin complexes and pharmaceutical compositions containing the same.
FI953590A (fi) Erittäin liukoiset monta komponenttia sisältävät sulkeumakompleksit, jotka sisältävät emästyyppistä lääkeainetta, happoa sekä syklodekstriiniä
EP0262344A3 (de) N-alkylierte quartäre stickstoffhaltige Heterozyklen, Verfahren zu deren Herstellung und deren Verwendung in Arzneimitteln
IL124674A0 (en) Piperazine derivatives pharmaceutical compositions containing the same and use thereof
ES2157993T3 (es) Benzoilguanidinas, su preparacion y su uso en medicamentos.
AU2307695A (en) High solubility multicomponent inclusion complexes consisting of an acidic drug, a cyclodextrin and a base
HK1038179A1 (en) New oral formulation for 5-ht4 agonists or antagonists
GEP20002206B (en) Cryptophycins, Method for its Production, Pharmaceutical Composition on Their basis and Use
GEP20063972B (en) Streptogramin derivatives, preparation and compositions containing them
NZ300942A (en) 1-aryl-2-acylamino-ethane derivatives as neurokinin 1 antagonists
NO950243L (no) Nye nimesulidsalt-cyklodekstrin-inklusjonskomplekser
AU1031697A (en) Novel geranylgeranyl-derivatives, process for the preparation thereof and related pharmaceutical compositions
AU8221291A (en) Cyclopentane derivatives, process for producing them and their pharmaceutical use
KR930702004A (ko) 세파로스포란 산 유도체를 함유하는 정제를 제조하기 위한 직접 압축 방법
AU4925200A (en) Oral composition containing perlite
CZ20022240A3 (cs) Mannichovy báze substituovaného 1-a 2-naftolu
AU667294B2 (en) Cyclopentane ether derivatives, methods for preparing them and their use in pharmaceuticals
ES2186369T3 (es) Imidazotriazolopirimidinas en calidad de medicamentos con efecto antagonista de adenosina.
HRP20000683B1 (hr) Postupak za dobivanje r-(+)-6-karboksamido-3-n-metilamino-1,2,3,4-tetrahidrokarbazola
AU2658601A (en) Pharmaceutical composition comprising carriers for products based on vitamin-e, papain and hyaluronidase
GR3021761T3 (en) Leukotriene-b 4? derivatives, process for preparing the same and medicaments.
AU1192097A (en) 3-aminoethyl-n-amidino-2,5-dihydropyrrole derivatives having arginine mimetic properties
AU2157197A (en) Dimethyl-substituted cyclohexadiene derivatives
MX9603722A (es) Nuevos pseudopeptidos sustituidos con heterociclos.
BR0201935C2 (pt) Sistema de comutação de voz e dados baseado em um banco de dados